Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will select all recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months. To observe the early relapse of atrial fibrillation and the changes of white blood cell count, hs-C reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α, and the changes of safety indicators .

This study assumes that the early atrial fibrillation (AF) recurrence will be decreased in patients with paroxysmal AF if rosuvastatin 20mg/d is received from 7 days before surgery in these patients who plan to undergo radiofrequency catheter ablation for consecutive 3 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Third Xiangya Hospital of Central South University
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures;

2. Age from 18 to 75 years old, male or female;

3. The course of paroxysmal AF is more than 3 months and confirmed by ECG;

4. Plan to undergo radiofrequency catheter ablation

Exclusion Criteria:

1. Concomitant with serious organic heart disease such as valvular heart diseases, congenital heart diseases, hypertrophic obstructive cardiomyopathy, acute myocardial infarction and unstable angina pectoris;

2. Concomitant with sinoatrial node functional disorder and (or) atrioventricular block;

3. Acute cerebral apoplexy or contraindication of anticoagulant;

4. Thyroid function abnormality;

5. Accepted radiofrequency catheter ablation (RFCA) previously;

6. Being receiving other statins;

7. Be allergic to statins;

8. Pregnancy or women during lactation period;

9. Be not aligning to treatment or follow-up due to mental disorders or other reasons;

10. Be with myopathy or active hepatopathy including agnogenic persistent elevation of serum transaminase and any serum transaminase being over 3 times of upper limit of normal;

11. Be with serious renal dysfunction (creatinine≥3 mg/dL);

12. Need steroid or non-steroid anti-inflammatory drugs to treat inflammation.